Gynecologic Cancer News

In 2018, infections were the cause of 13% of all new cancer diagnoses, totaling 2.2 million new cases worldwide, although these totals do not include nonmelanoma skin cancers, according to findings published in The Lancet Global Health.

CA-125 is a “useful test” for ovarian cancer in primary care, especially in symptomatic women aged older than 50 years, according to a presenter at the recent National Cancer Research Institute Cancer Conference in Glasgow.

In this supplement to HemOnc Today, we have compiled the most-read articles written about ovarian cancer this year. From risk reducing measures (below) to improving progression-free survival (pages 12 and 14), our experts researched and weighed in on the spectrum of this deadly carcinoma. “These are exciting times in ovarian cancer research and, more importantly, for patients. Recent discoveries have realized the possibility that this is the beginning of the end of ovarian cancer,” Michael J. Birrer, MD, PhD, writes in his editorial (page 10). “Our new understanding of the origins of this disease may give rise to a reasonably effective early detection assay, which remains the holy grail of ovarian cancer research.” To follow along this journey, be sure to follow @HemOncToday on Twitter and visit Healio.com regularly.

The Partnership for Aging and Cancer Research Program awarded seven grants intended to fund research into the link between aging and cancer.

Two novel blood assays demonstrated efficacy in detecting various cancer types at different disease stages, according to results of two studies presented at ASCO Breakthrough in Bangkok.

Secondary surgical cytoreduction followed by chemotherapy did not extend OS compared with chemotherapy alone among women with platinum-sensitive, recurrent epithelial ovarian cancer, according to results of the randomized phase 3 GOG-0213 study published in The New England Journal of Medicine.

NATIONAL HARBOR, Md. — An investigational bispecific T-cell engager appeared safe and demonstrated some clinical activity among patients with HER2-positive solid tumors, according to phase 1 dose-escalation study data presented at Society for Immunotherapy of Cancer Annual Meeting.

Hyperbaric oxygen therapy safely relieved symptoms of late radiation cystitis among patients who received radiotherapy for cancer in the pelvic region, according to results of the randomized phase 2/phase 3 RICH-ART trial published in The Lancet Oncology.

The FDA office that reviews applications for cancer therapies has been renamed and reorganized.

The FDA expanded the approval of niraparib for gynecologic cancers.